Sellas $SLS shares rose 12% yesterday on expectations of data being released from the Phase 3 REGAL clinical trial for asymptomatic leukemia (AML) treatment and the announcement that the CEO will appear on the Fox & Friends program next week.

SLS12.13%
post-image
post-image
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned